Control Bionics launches NeuroStrip app on Apple and Microsoft stores in global scaling push
Control Bionics (ASX: CBL) has launched its NeuroStrip app across Apple’s App Store, the Mac App Store and the Microsoft Store, making the Company’s wearable sensor platform more accessible on commonly used devices as at 12 August 2026.
The app is free-to-download and enables customers to connect to and use the NeuroStrip platform through their existing compatible devices, without requiring custom software installation. This removes a distribution barrier and supports the Company’s stated strategy to grow recurring software and subscription revenue.
The milestone is positioned as a scalability step rather than a one-off release, broadening the addressable audience well beyond direct sales channels.
When big ASX news breaks, our subscribers know first
What NeuroStrip is and why the app matters
NeuroStrip is Control Bionics’ proprietary wearable surface electromyography (sEMG) sensor platform. In plain terms, sEMG non-invasively captures the electrical activity generated by muscles and converts it into measurable data, with no surgery or implantation required.
The platform is designed for use across three settings: elite sports performance, clinical rehabilitation, and research settings. It serves four primary end-user groups:
NeuroStrip commercial expansion across the same five target markets has been building since mid-2026, with structured evaluation programs running at AFL clubs, NRL clubs, and the Australian Institute of Sport, alongside a Japan-based stroke study that reported a 39% reduction in muscle overactivity using the platform.
-
Clinicians
-
Physiotherapists
-
Researchers
-
Sporting organisations
For investors, the significance lies in the channel. Distributing software via major app stores is a more scalable route than direct distribution, aligning with a recurring software and subscription revenue model.
The investment case — scaling a recurring revenue model
The rationale, according to management, centres on removing friction, enabling scalable distribution and support, and growing recurring software and subscription revenue. The app launch builds on growing customer engagement across Australia, New Zealand, the United States, Europe and Japan.
Jeremy Steele, CEO and Managing Director
“Making NeuroStrip available through major app stores removes friction for customers and provides a more scalable way to distribute and support the platform globally. It expands access to our technology and supports our strategy to grow recurring software and subscription revenue.”
Steele added that the change alters how customers access the technology. “Our customers can now find and use our software the same way they access everything else on their devices. It opens the platform to a far wider audience than we could reach through direct distribution alone,” he said.
The combination of wider audience reach and a subscription-based model points to the potential for scalable revenue growth over time, though no revenue figures have been disclosed.
Regulatory position and next steps
An important distinction sits beneath the launch. While the app is free and globally accessible, NeuroStrip hardware is supplied only in markets where the Company holds the applicable regulatory registrations. The app’s global availability should not be read as global hardware availability.
The current regulatory position is as follows:
-
NeuroStrip holds US FDA establishment registration and device listing
-
Regulatory applications are progressing in Australia and the European Union
-
The Company’s separate NeuroNode system holds regulatory clearances in the US, Australia and Europe
-
Control Bionics is a registered NDIS provider in Australia
The table below summarises the key developments and their potential relevance for investors.
| Development | Detail | Investor Impact |
|---|---|---|
| App launch | Live on Apple, Mac & Microsoft stores, free-to-download | Lower-friction, scalable global distribution |
| Revenue model | Supports recurring software/subscription revenue | Potential for recurring software and subscription revenue |
| US regulatory | FDA establishment registration & device listing | Enables hardware supply in the US market |
| AU/EU regulatory | Applications progressing | Potential future market expansion |
No revenue figures, subscription pricing, user numbers or contract values were disclosed in the announcement, and the app launch is not stated to have generated revenue.
What comes next for Control Bionics
The app launch is positioned as an enabler of broader global reach across the five named markets of Australia, New Zealand, the United States, Europe and Japan. The progressing regulatory applications in Australia and the European Union stand as the key ongoing catalysts for investors to watch, with the app release framed as one step in the Company’s stated global scaling strategy.
For investors exploring how Control Bionics has been building its US commercial infrastructure ahead of this app launch, our detailed coverage of the PRC-Saltillo distribution deal outlines the capital-efficient partnership model, trained sales network, and insurance funding pathways already in place for the NeuroNode division.
Don’t Miss the Next Healthcare Breakout on ASX
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already ahead of the market. Click the “Free Alerts” button at StockWire X to get the next market-moving announcement the moment it drops.